Survodutide

Overview

Survodutide is an investigational dual agonist at GLP-1 and glucagon receptors. It sits in the next-generation metabolic-drug category, where researchers are testing whether glucagon-receptor activity can add energy-expenditure and liver-metabolism effects to GLP-1-based appetite regulation.

The Science

Survodutide's profile differs from semaglutide and tirzepatide because it includes glucagon receptor agonism.

• GLP-1 signaling - appetite, glucose-dependent insulin secretion, glucagon suppression, and gastric-emptying effects.
• Glucagon signaling - hepatic metabolism, energy-expenditure hypotheses, and liver-fat research.
• MASH research - interest includes liver inflammation, steatosis, and fibrosis-related endpoints.

Evidence Snapshot

Survodutide has human phase 2 evidence in obesity and MASH, but it remains investigational. Research interpretation should track current clinical-trial status and separate single-agent data from vendor stack claims.

References

1. [1]le Roux CW et al. Survodutide for obesity: phase 2 dose-finding trial(2024) · doi:10.1016/S2213-8587(23)00356-X
2. [2]Sanyal AJ et al. Survodutide in MASH and fibrosis: phase 2 trial(2024) · doi:10.1056/NEJMoa2401755